» Articles » PMID: 2483948

An Endothelial Cell Growth Factor from the Mouse Neuroblastoma Cell Line NB41

Overview
Journal Growth Factors
Publisher Informa Healthcare
Specialty Biology
Date 1989 Jan 1
PMID 2483948
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

A growth factor that stimulates the proliferation of endothelial cells from human umbilical vein but is not mitogenic for fibroblastic cells is present in medium conditioned by the mouse neuroblastoma cell line NB41. In a partially purified preparation, factor activity coeluted from a reverse-phase high-pressure liquid chromatography (HPLC) column with a reduced protein of about 24 kd. Activity recovered following electrophoresis of HPLC fractions corresponded to protein of 43-51 kd in the absence of reducing agent and to protein of 23-29 kd after reduction. Antiserum raised against a peptide corresponding to the putative N-terminal amino acid sequence of the 24-kd protein reacted with the 24-kd protein and with a protein of about 47 kd in the nonreduced preparation. After N-glycanase treatment, the immunoreactive 24-kd protein had a mobility corresponding to 19 kd. We infer that the native NB41 factor is a glycosylated dimer whose biochemical and biological properties distinguish if from other endothelial cell growth factors.

Citing Articles

Antitumor effects of 2-oxoglutarate through inhibition of angiogenesis in a murine tumor model.

Matsumoto K, Obara N, Ema M, Horie M, Naka A, Takahashi S Cancer Sci. 2009; 100(9):1639-47.

PMID: 19575748 PMC: 11159297. DOI: 10.1111/j.1349-7006.2009.01249.x.


VEGF enhances intraneural angiogenesis and improves nerve regeneration after axotomy.

Hobson M, Green C, Terenghi G J Anat. 2001; 197 Pt 4:591-605.

PMID: 11197533 PMC: 1468175. DOI: 10.1046/j.1469-7580.2000.19740591.x.


The role of the vascular phase in solid tumor growth: a historical review.

Ribatti D, Vacca A, Dammacco F Neoplasia. 2000; 1(4):293-302.

PMID: 10935483 PMC: 1508099. DOI: 10.1038/sj.neo.7900038.


[Vascular endothelial factor (VEGF): therapeutic angiogenesis and vasculogenesis in the treatment of cardiovascular disease].

Kalka C, Takahashi T, Masuda H, Asahara T, Isner J Med Klin (Munich). 1999; 94(4):193-201.

PMID: 10373754 DOI: 10.1007/BF03044854.


Angiogenesis and vasculogenesis in treatment of cardiovascular disease.

Rivard A, Isner J Mol Med. 1998; 4(7):429-40.

PMID: 9713822 PMC: 2230333.